---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-258780"
form_type: "8-K"
ticker: "DBVT"
cik: "0001613780"
company_name: "DBV Technologies S.A."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:20:45.865786+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# DBV Technologies appoints Philina Lee to Board of Directors effective October 30, 2025

## Summary
- Lee replaces Daniel Soland; appointment subject to shareholder ratification at next annual meeting.
- She previously served as Chief Commercial Officer of Blueprint Medicines, leading AYVAKIT launch.
- Lee will serve on the Compensation Committee of the Board.
- She will receive an annual retainer of €100,000 plus €5,000 for committee service.
- Company now has ten board members; Lee brings biopharma commercialization experience.

## SEC filing metadata
- accession: 0001193125-25-258780
- form_type: 8-K
- ticker: DBVT
- cik: 0001613780
- company_name: DBV Technologies S.A.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613780/000119312525258780/0001193125-25-258780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613780/000119312525258780/d82861d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-258780
- JSON: https://secwatch.observer/filing/0001193125-25-258780.json
- Plain text: https://secwatch.observer/filing/0001193125-25-258780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.